These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24692859)

  • 1. Immunotoxins: a review of their use in cancer treatment.
    Aruna G
    J Stem Cells Regen Med; 2006; 1(1):31-6. PubMed ID: 24692859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of antibodies for cancer therapy.
    Wilkins DK; Mayer A
    Expert Opin Biol Ther; 2006 Aug; 6(8):787-96. PubMed ID: 16856800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant immunotoxins for cancer therapy.
    Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
    Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Receptors on Cancer Cells with Protein Toxins.
    Antignani A; Ho ECH; Bilotta MT; Qiu R; Sarnvosky R; FitzGerald DJ
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32957689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic antibodies.
    Groner B; Hartmann C; Wels W
    Curr Mol Med; 2004 Aug; 4(5):539-47. PubMed ID: 15267225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrax fusion protein therapy of cancer.
    Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
    Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of immunotoxins: current progress and future prospects.
    Wawrzynczak EJ
    Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies to selectively kill cancer cells.
    Panchal RG
    Biochem Pharmacol; 1998 Feb; 55(3):247-52. PubMed ID: 9484789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug targeting with monoclonal antibodies. A review.
    Blakey DC
    Acta Oncol; 1992; 31(1):91-7. PubMed ID: 1637417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.
    Niv R; Cohen CJ; Denkberg G; Segal D; Reiter Y
    Curr Pharm Biotechnol; 2001 Mar; 2(1):19-46. PubMed ID: 11482347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.
    Blythman HE; Casellas P; Gros O; Gros P; Jansen FK; Paolucci F; Pau B; Vidal H
    Nature; 1981 Mar; 290(5802):145-6. PubMed ID: 7207595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.
    Vitetta ES
    J Clin Immunol; 1990 Nov; 10(6 Suppl):15S-18S. PubMed ID: 2081785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.